To understand the impact of systemic CD4 and CD8 T‐cell immunity before the start of immunotherapies, we carried out a discovery study in a cohort sample of 51 NSCLC patients undergoing PD‐1/PD‐L1 immune checkpoint blockade therapy after progression to platinum‐based chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.